GlassScriptPhysician profile
Chad L Carter
NPI 1255323648
$8,666.65
in general payments reported to CMS, 2019-2025
26 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $759 · 2021: $1,297 · 2022: $950 · 2023: $1,031 · 2024: $1,822 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,168.72 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,641.79 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Rocklatan |
| Glaukos Corporation | $1,171.63 | 2019-2025 | Istent Infinite, Idosetr, Idose |
| Johnson & Johnson Surgical Vision, INC. | $834.01 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Horizon Therapeutics Plc | $680.90 | 2021-2023 | Tepezza |
| Sight Sciences, INC. | $620.56 | 2019-2025 | Tearcare System, Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $571.93 | 2019-2025 | Cequa |
| Coopervision INC. | $512.20 | 2022-2025 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $421.23 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $377.15 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $324.62 | 2019-2020 | |
| Shire North American Group INC | $309.75 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $211.73 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $181.82 | 2019 | |
| Abbvie INC. | $155.67 | 2024-2025 | |
| Lkc Technologies, INC. | $137.56 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $122.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $71.74 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $63.76 | 2024-2025 | Acthar |
| Maculogix, INC. | $58.58 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $45.77 | 2021 | |
| Lensar, INC. | $36.07 | 2019-2024 | Lensar Laser System |
| Harrow Eye, LLC | $28.71 | 2025 | Vevye |
| Amgen INC. | $25.43 | 2025 | Tepezza |
| Lumenis, INC | $25.40 | 2021 | |
| Ocular Therapeutix, INC. | $23.03 | 2023 | Dextenza |
| Oyster Point Pharma, INC. | $13.31 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.